Our corporate vision as a biotech company is to improve and save lives through the development of treatments for cancer, infectious disease, and the chronic inflammation intrinsic to autoimmune disease.

VG Life Sciences aims to improve and save lives through the development of transformative therapies for drug-resistant cancers and autoimmune diseases. We are moving forward to achieve our vision through the research and development of drugs using two platform technologies, Targeted Peptide Technology (TPT) and Metabolic Disruption Technology (MDT). Our efforts on our revolutionary TPT drug, VG1177, for which we were issued a composition-of-matter patent (Patent No: US 8,957,031), are focused on accelerating progression from the research laboratory, to pre-clinical studies, and to clinical trials. The VG1177 peptide prevents the survival of pro-inflammatory cells that give rise to autoimmune diseases and other disorders. We have completed a pre-investigational new drug meeting with the FDA (IND # 110820) and initiated preclinical work in November 2013 with our animal safety and toxicity study, a prerequisite for clinical trials. Concurrently, we are continuing research at our laboratory at Texas A&M Health Sciences Center under the direction of VG Life Sciences’ Chief Scientist, Dr. M. Karen Newell-Rogers, Ph.D. Collaborating with research scientists from institutions around the country, Dr. Newell-Rogers is actively pursuing applications of VG1177 in the following diseases:
HIV/AIDS Hypertension Brain Trauma Glioblastoma Preeclampsia Type I & II Diabetes Heart Failure Lyme Disease Multiple Sclerosis Autoimmune Myocarditis Lymphedema Rheumatoid Arthritis Alzheimer's Crohn's/Ulcerative Colitis
Meanwhile, promising Phase 1 results and our scientific expertise continue to propel our MDT combination therapy for drug-resistant cancers (US Patent Application No. 12/918741) through the clinic. We believe MDT technology interferes with cancer cells’ ability to acquire energy, making them more susceptible to cancer-killing agents and more visible and vulnerable to the immune system. In September 2014, the primary investigator of the Phase 1 study at the University of Texas, Dr. Tyler Curiel, M.D., M.P.H., concluded that there were no adverse effects and the maximum dose and schedule are sufficiently safe for additional clinical testing. Additionally, we saw encouraging signs of efficacy during the toxicity studies. VG Life Sciences is in discussion with the University of Texas regarding the feasibility of expanding the study into an expanded Phase 1 or Phase 2 study.